

## ACKNOWLEDGEMENTS

---

- The research leading to these results was conducted as part of the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, [www.imi-protect.eu](http://www.imi-protect.eu)) which is a public-private partnership coordinated by the European Medicines Agency.
- The PROTECT project has received support from the Innovative Medicines Initiative Joint Undertaking ([www.imi.europa.eu](http://www.imi.europa.eu)) under Grant Agreement n° 115004, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.
- The views expressed are those of the authors only.

